Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipifarnib - Kura Oncology

Drug Profile

Tipifarnib - Kura Oncology

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 19 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
  • Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Quinolones; Small molecules
  • Mechanism of Action CXCL12 protein inhibitors; Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II Chronic myelomonocytic leukaemia; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Preclinical Cutaneous T-cell lymphoma
  • Discontinued Breast cancer; Glioblastoma

Most Recent Events

  • 05 Nov 2019 Kura Oncology has patent protection for tipifarnib for treatment of Peripheral T-cell lymphoma and Acute myeloid leukaemia in USA
  • 29 Oct 2019 Safety and efficacy data from a phase II trial in Head and neck cancer presented at the ACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (ACR-NCI-EORTC-2019)
  • 03 Sep 2019 Efficacy and adverse events data from a phase II trial in Urogenital cancer (Late-stage disease, Second-line therapy or greater) released by Kura Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top